Older adults with ESDLBCL achieved favourable long-term outcomes, with competing non-lymphoma mortality playing a major role. The KHCC-EPI improves risk stratification beyond Sa-IPI and warrants external validation to guide treatment optimisation in this population.
Ma’koseh et al. (Wed,) studied this question.